[go: up one dir, main page]

NO20060091L - Anvendelse av kondenserte heterocykliske forbindelser som SCCE-inhibitorer for behandling av hudproblemer eller kreft - Google Patents

Anvendelse av kondenserte heterocykliske forbindelser som SCCE-inhibitorer for behandling av hudproblemer eller kreft

Info

Publication number
NO20060091L
NO20060091L NO20060091A NO20060091A NO20060091L NO 20060091 L NO20060091 L NO 20060091L NO 20060091 A NO20060091 A NO 20060091A NO 20060091 A NO20060091 A NO 20060091A NO 20060091 L NO20060091 L NO 20060091L
Authority
NO
Norway
Prior art keywords
cancer
treatment
skin problems
scce
condensed heterocycles
Prior art date
Application number
NO20060091A
Other languages
English (en)
Inventor
Marcel Linschoten
Original Assignee
Arexis Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arexis Ab filed Critical Arexis Ab
Publication of NO20060091L publication Critical patent/NO20060091L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Det beskrives heterosykliske inhibitorer av stratumcorneurnkymotryptisk enzym (SCCE). Mer spesielt beskrives anvendelsen av forbindelser med formel (I) eller (II) for behandling av visse sykdommer og særlig hudsykdommer som pruritt og også cancer som ovariecancer.
NO20060091A 2003-06-06 2006-01-06 Anvendelse av kondenserte heterocykliske forbindelser som SCCE-inhibitorer for behandling av hudproblemer eller kreft NO20060091L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200300844 2003-06-06
DKPA200300843 2003-06-06
DKPA200300842 2003-06-06
DKPA200300840 2003-06-06
PCT/DK2004/000388 WO2004108139A2 (en) 2003-06-06 2004-06-07 Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer

Publications (1)

Publication Number Publication Date
NO20060091L true NO20060091L (no) 2006-03-06

Family

ID=33514772

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060091A NO20060091L (no) 2003-06-06 2006-01-06 Anvendelse av kondenserte heterocykliske forbindelser som SCCE-inhibitorer for behandling av hudproblemer eller kreft

Country Status (17)

Country Link
US (1) US7872052B2 (no)
EP (1) EP1631295B1 (no)
JP (1) JP5044214B2 (no)
KR (2) KR101205257B1 (no)
CN (1) CN101152185B (no)
AT (1) ATE459359T1 (no)
CA (1) CA2525383C (no)
CY (1) CY1110084T1 (no)
DE (1) DE602004025803D1 (no)
DK (1) DK1631295T3 (no)
ES (1) ES2341545T3 (no)
NO (1) NO20060091L (no)
NZ (1) NZ543636A (no)
PL (1) PL1631295T3 (no)
PT (1) PT1631295E (no)
SI (1) SI1631295T1 (no)
WO (1) WO2004108139A2 (no)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
US8044060B2 (en) 2003-05-09 2011-10-25 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
DE10320785A1 (de) * 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Arylmethyl-substituierte Pyrazolopyrimidine
DE102004001873A1 (de) * 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
US8410109B2 (en) * 2005-07-29 2013-04-02 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
PL2066662T3 (pl) 2006-09-21 2013-05-31 Kyorin Seiyaku Kk Inhibitory hydrolaz serynowych
WO2008041118A2 (en) 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
AU2007345526B2 (en) 2007-02-01 2013-02-28 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
PL2183273T3 (pl) 2007-08-17 2017-09-29 Novartis Ag Cykliczne depsypeptydy
WO2009024528A1 (en) 2007-08-17 2009-02-26 Novartis Ag Use of cyclic depsipeptides to inhibit kallikrein 7
PE20091211A1 (es) 2007-11-30 2009-09-14 Boehringer Ingelheim Int Derivados de pirazolopirimidina como moduladores de pde9a
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
EP2334684B1 (en) 2008-09-08 2017-08-02 Boehringer Ingelheim International GmbH Pyrazolopyrimidines and their use for the treatment of cns disorders
NZ594332A (en) 2009-01-08 2013-09-27 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular disease
EP2403857B1 (en) * 2009-03-05 2013-12-04 Takeda Pharmaceutical Company Limited Thienopyrimidine as cdc7 kinase inhibitors
KR101709492B1 (ko) 2009-03-18 2017-02-23 리스버로직스 코퍼레이션 신규한 소염제
CA2757231A1 (en) 2009-03-31 2010-10-07 Boehringer Ingelheim International Gmbh 1-heterocyclyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
ES2706651T3 (es) 2009-04-22 2019-03-29 Resverlogix Corp Nuevos agentes antiinflamatorios
TWI419884B (zh) * 2010-06-24 2013-12-21 Univ Chang Gung 苯并雜氧嗪酮衍生物，其製備方法以及包含有此等衍生物的藥學組成物
KR101918909B1 (ko) 2010-08-12 2018-11-15 베링거 인겔하임 인터내셔날 게엠베하 ６­사이클로알킬­１，５­디하이드로­피라졸로［３，４­ｄ］피리미딘­４­온 유도체 및 이의 ｐｄｅ９ａ 억제제로서의 용도
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
US8614289B2 (en) 2011-04-20 2013-12-24 Novartis Ag Processes for the manufacture of macrocyclic depsipeptides and new intermediates
US8680054B2 (en) 2011-04-20 2014-03-25 Novartis Ag Suspension type topical formulations comprising cyclic depsipeptide
SI2773354T1 (sl) 2011-11-01 2019-08-30 Resverlogix Corp. Peroralne formulacije s takojšnjim sproščanjem za substituirane kinazolinone
HK1207072A1 (en) 2012-03-16 2016-01-22 埃克希金医药品有限公司 3,5-diaminopyrazole kinase inhibitors
UA125503C2 (uk) 2012-06-13 2022-04-13 Інсайт Холдинґс Корпорейшн Заміщені трициклічні сполуки як інгібітори fgfr
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US8987413B2 (en) 2012-10-09 2015-03-24 Novartis Ag Aldehyde acetal based processes for the manufacture of macrocyclic depsipeptides and new intermediates
US9067978B2 (en) 2012-10-09 2015-06-30 Novartis Ag Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
KR20150096794A (ko) 2012-12-21 2015-08-25 제니쓰 에피제네틱스 코포레이션 브로모도메인 저해제로서의 신규한 헤테로사이클릭 화합물
WO2014172644A2 (en) 2013-04-19 2014-10-23 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
JP6552010B2 (ja) * 2014-01-23 2019-07-31 シクセラ ファーマ エービー 新しいカリクレイン７阻害剤
PT3097085T (pt) 2014-01-23 2020-10-08 Sixera Pharma Ab Derivados de benzoxazinona para tratamento de doenças de pele
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EA032473B1 (ru) 2014-12-23 2019-05-31 Аксикин Фармасьютикалз, Инк. 3,5-диаминопиразоловые ингибиторы киназы
UA121669C2 (uk) 2015-02-20 2020-07-10 Інсайт Корпорейшн Біциклічні гетероцикли як інгібітори fgfr
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
KR102662814B1 (ko) 2015-03-13 2024-05-03 리스버로직스 코퍼레이션 보체 관련 질환을 치료하기 위한 조성물 및 치료 방법
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
EP3694861A4 (en) 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
EP3694509A4 (en) 2017-10-09 2021-07-14 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND THEIR USES
CN108421034A (zh) * 2018-04-24 2018-08-21 济南磐升生物技术有限公司 激肽释放酶7在皮肤创伤愈合中的应用
CN112566912A (zh) 2018-05-04 2021-03-26 因赛特公司 Fgfr抑制剂的盐
SI3788047T1 (sl) 2018-05-04 2024-11-29 Incyte Corporation Trdne oblike inhibitorja fgfr in postopki priprave le-teh
TWI803696B (zh) 2018-09-14 2023-06-01 日商橘生藥品工業股份有限公司 次黃嘌呤化合物
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
MX2021012418A (es) 2019-04-09 2021-11-12 Nuvation Bio Inc Compuestos heterociclicos y sus usos.
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
BR112022005881A2 (pt) 2019-10-01 2022-06-21 Molecular Skin Therapeutics Inc Compostos de benzoxazinona como inibidores duplos de klk5/7
EP4045151A1 (en) 2019-10-14 2022-08-24 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4069695A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Derivatives of an fgfr inhibitor
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP7502945B2 (ja) * 2020-09-08 2024-06-19 花王株式会社 デリケートエリアのかぶれの検査方法
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
CN117396188A (zh) 2021-06-01 2024-01-12 西可斯拉制药公司 6-乙氧基-7-甲氧基-2-(2-甲基硫基苯基)-3,1-苯并噁嗪-4-酮的水包油乳液
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
JP2025521540A (ja) * 2022-06-21 2025-07-10 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 縮合二環式ｅｇｆｒ阻害剤およびその使用の方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1153994A (en) * 1965-07-21 1969-06-04 Aspro Nicholas Ltd Hydroxyphenyl Anthranilic Acid Derivatives Capable of Absorbing 'Ultra-Violet Light and Compositions containing them
FR2121341A1 (en) * 1971-01-04 1972-08-25 Ferlux 2-substd-3,1-benzoxazin-4-ones - antiinflammatories, analgesics sedatives and diuretics
IT1050750B (it) * 1975-12-05 1981-03-20 Erba Carlo Spa Derivati della 3.4 di idro chinazolina
JPS5576868A (en) 1978-12-01 1980-06-10 Hisamitsu Pharmaceut Co Inc Novel 3,1-bezoxazine derivative
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
FI912995A7 (fi) * 1988-12-21 1991-06-19 Upjohn Co Antiateroskleroottisia ja antitromboottisia 1-bentsopyran-4-oneja ja 2 -amino-1,3-bentsoksatsin-4-oneja
JPH07316056A (ja) * 1990-02-15 1995-12-05 Teijin Ltd エラスターゼ阻害用医薬組成物
AU635403B2 (en) * 1990-02-15 1993-03-18 Teijin Limited 4h-3,1-benzoxazin-4-one compound and elastase inhibitor composition containing the same
WO1991019707A2 (en) * 1990-06-20 1991-12-26 The Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
SG64322A1 (en) 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5346886A (en) * 1993-11-15 1994-09-13 John Lezdey Topical α-1-antitrypsin, non-aqueous lipid miscible, benzalkonium chloride compositions for treating skin
AU1375000A (en) * 1998-11-26 2000-06-13 Novo Nordisk A/S Heterocyclic compounds regulating clotting
EP1438073B1 (en) * 1999-09-10 2010-08-11 The Procter & Gamble Company Polyoxyalkylene conjugates as enzyme inhibitors
PT1367886E (pt) 2001-02-09 2011-10-03 Torbjoern Egelrud Ratinhos transgénicos scce e sua utilização como modelos de doença humana
AU2002317377A1 (en) * 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
CA2503674A1 (en) * 2002-10-03 2004-04-15 Institute Of Medicinal Molecular Design, Inc. Quinazolin-4-one derivatives
CA2502302A1 (en) * 2002-11-04 2004-05-21 Nps Pharmaceuticals, Inc. Quinazolinone compounds as calcilytics
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS

Also Published As

Publication number Publication date
KR101205257B1 (ko) 2012-11-27
KR20060008331A (ko) 2006-01-26
US20060258651A1 (en) 2006-11-16
WO2004108139A2 (en) 2004-12-16
CN101152185A (zh) 2008-04-02
JP2006526581A (ja) 2006-11-24
CA2525383A1 (en) 2004-12-16
ATE459359T1 (de) 2010-03-15
HK1091731A1 (zh) 2007-01-26
AU2004244704A1 (en) 2004-12-16
KR20110120960A (ko) 2011-11-04
NZ543636A (en) 2009-07-31
SI1631295T1 (sl) 2010-06-30
CY1110084T1 (el) 2015-01-14
CA2525383C (en) 2012-03-06
WO2004108139A8 (en) 2005-04-28
EP1631295B1 (en) 2010-03-03
CN101152185B (zh) 2010-12-08
JP5044214B2 (ja) 2012-10-10
DK1631295T3 (da) 2010-06-21
DE602004025803D1 (de) 2010-04-15
EP1631295A2 (en) 2006-03-08
US7872052B2 (en) 2011-01-18
PT1631295E (pt) 2010-05-24
ES2341545T3 (es) 2010-06-22
KR101099409B1 (ko) 2011-12-27
PL1631295T3 (pl) 2010-09-30
WO2004108139A3 (en) 2005-03-10
HK1120209A1 (en) 2009-03-27

Similar Documents

Publication Publication Date Title
NO20060091L (no) Anvendelse av kondenserte heterocykliske forbindelser som SCCE-inhibitorer for behandling av hudproblemer eller kreft
NO20065148L (no) Monocykliske heterocykler som kinase inhibitorer
NO20081636L (no) FAP - inhibitorer
EA200702048A1 (ru) Фармакокинетически улучшенные соединения
TNSN08227A1 (en) [4-(benzo [b] thi0phen-2-yl) pyrimidin-2yl] -amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases.
EA201000915A1 (ru) Ингибиторы пролилгидроксилазы
EA200601391A1 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
EA200800555A1 (ru) Производные ксантина в качестве селективных агонистов hm74a
IL187328A (en) N-methyl-2-fluoro-{4-[3-(4-cyano-3-trifluoromethylphenyl)-5,5-dimethyl-4-oxo-2-thioxo-imidazolidin-1-yl]}benzamide, pharmaceutical compositions comprising the same and uses thereof in the manufacture of medicaments
EA200701771A1 (ru) Низкомолекулярные ингибиторы mdm2 и их применение
DE50310516D1 (de) Fredericamycin-derivate
NO20044995L (no) Heterosykliske forbindelser
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
EA200700168A1 (ru) Производные замещенной циклической мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназы
PE20080948A1 (es) Derivados de imidazol como moduladores de la senda de hedgehog
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
EA201170344A1 (ru) Азаиндольные ингибиторы iap
EA200701930A1 (ru) Производные пиримидина для лечения гиперпролиферативных нарушений
EA201170828A1 (ru) Конденсированные гетероциклические производные оксадиазола, подходящие для лечения рассеянного склероза
EA200870089A1 (ru) Применение производных бензоконденсированного гетероциклического сульфамида для лечения злоупотребления психоактивным веществом и аддикции
DE60328603D1 (de) Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
DE60329326D1 (de) Tace inhibitoren
DK1885187T3 (da) Fremgangsmåde til behandling af lægemiddelresistent cancer
UA85087C2 (en) Monocyclic heterocycles as kinase inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application